neoplasms

Low skeletal muscle mass and treatment outcomes among adults with haematologic malignancies: A systematic review and meta-analysis.

Low skeletal muscle mass (LSMM) and/or, function associated with an increased risk of treatment-related toxicities and inferior overall survival (OS) among adults with solid malignancies. However, the association between LSMM and treatment-related toxicities among adults with haematologic malignancies remains unclear....

🗓️ 2024-04-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreLow skeletal muscle mass and treatment outcomes among adults with haematologic malignancies: A systematic review and meta-analysis.

Co-morbid sarcopenia and low bone mineral density in young paediatric cancer survivors.

Sarcopenia and low areal bone mineral density (aBMD) are prevalent musculoskeletal complications after paediatric cancer treatment. However, their relationship has not been examined in young paediatric cancers survivors. This study aimed to evaluate aBMD differences according to sarcopenia status and...

🗓️ 2024-08-20
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreCo-morbid sarcopenia and low bone mineral density in young paediatric cancer survivors.

Sarcopenia is independently associated with poor preoperative physical fitness in patients undergoing colorectal cancer surgery.

Accurate preoperative risk assessment for major colorectal cancer (CRC) surgery remains challenging. Body composition (BC) and cardiopulmonary exercise testing (CPET) can be used to evaluate risk. The relationship between BC and CPET in patients undergoing curative CRC surgery is unclear....

🗓️ 2024-06-26
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreSarcopenia is independently associated with poor preoperative physical fitness in patients undergoing colorectal cancer surgery.

Body weight and composition endpoints in cancer cachexia clinical trials: Systematic Review 4 of the cachexia endpoints series.

Significant variation exists in the outcomes used in cancer cachexia trials, including measures of body composition, which are often selected as primary or secondary endpoints. To date, there has been no review of the most commonly selected measures or their...

🗓️ 2024-05-13
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreBody weight and composition endpoints in cancer cachexia clinical trials: Systematic Review 4 of the cachexia endpoints series.

Frequency of weight and body composition increases in advanced non-small cell lung cancer patients during first line therapy.

The primary objective of this study was to assess the frequency of body composition increases and their relationships to changes in body weight in two cohorts of real world, treatment-naïve, advanced non-small cell lung cancer (NSCLC) patients. One cohort received...

🗓️ 2024-09-17
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreFrequency of weight and body composition increases in advanced non-small cell lung cancer patients during first line therapy.

IL36G-producing neutrophil-like monocytes promote cachexia in cancer.

Most patients with advanced cancer develop cachexia, a multifactorial syndrome characterized by progressive skeletal muscle wasting. Despite its catastrophic impact on survival, the critical mediators responsible for cancer cachexia development remain poorly defined. Here, we show that a distinct subset...

🗓️ 2024-09-12
📰 Publication: Nature Communications
Read MoreIL36G-producing neutrophil-like monocytes promote cachexia in cancer.

Ponsegromab for the Treatment of Cancer Cachexia.

Cachexia is a common complication of cancer and is associated with an increased risk of death. The level of growth differentiation factor 15 (GDF-15), a circulating cytokine, is elevated in cancer cachexia. In a small, open-label, phase 1b study involving...

🗓️ 2024-09-14
📰 Publication: New England Journal Of Medicine
Read MorePonsegromab for the Treatment of Cancer Cachexia.

Immunomodulation: A new approach to cancer cachexia, potentially suitable for aging.

Cancer cachexia is the prototypical example of comorbidity, occurring in most of cancer patients. It is a direct consequence of tumor growth and of the associated inflammatory/immune response. Cachexia can be exacerbated by anti-cancer therapies, frequently resulting in dose limitation...

🗓️ 2024-09-10
📰 Publication: Molecular Aspects Of Medicine
Read MoreImmunomodulation: A new approach to cancer cachexia, potentially suitable for aging.

-mutated NSCLC is Dependent on Tumor-secreted GDF15.

Cachexia is a wasting syndrome comprised of adipose, muscle, and weight loss observed in cancer patients. Tumor loss-of-function mutations in , a regulator of the energy sensor AMP-activated protein kinase, induce cancer cachexia (CC) in preclinical models and are associated...

🗓️ 2024-06-17
Read More-mutated NSCLC is Dependent on Tumor-secreted GDF15.

Defining and Addressing Research Priorities in Cancer Cachexia through Transdisciplinary Collaboration.

For many patients, the cancer continuum includes a syndrome known as cancer-associated cachexia (CAC), which encompasses the unintended loss of body weight and muscle mass, and is often associated with fat loss, decreased appetite, lower tolerance and poorer response to...

🗓️ 2024-06-27
Read MoreDefining and Addressing Research Priorities in Cancer Cachexia through Transdisciplinary Collaboration.

Correlates and predictors of sarcopenia among men with metastatic castrate-resistant prostate cancer.

Sarcopenia is a predictor of clinical outcomes in men with metastatic castrate-resistant prostate cancer (mCRPC); however, correlates and predictors of sarcopenia are poorly understood in this population. The aim of this study was to examine correlates and predictors of sarcopenia...

🗓️ 2024-07-15
📰 Publication: Cuaj-Canadian Urological Association Journal
Read MoreCorrelates and predictors of sarcopenia among men with metastatic castrate-resistant prostate cancer.

Assessing cachexia in obesity: contradiction or perfectly possible?

Existing definitions of clinically important weight loss in patients with cancer do not specifically address weight loss in patients who are obese at presentation. This review explores the clinical impact of weight loss and depletion of the skeletal muscle mass...

🗓️ 2024-07-04
📰 Publication: Current Opinion In Clinical Nutrition And Metabolic Care
Read MoreAssessing cachexia in obesity: contradiction or perfectly possible?

Validity of dietary intake methods in cancer cachexia.

Accurate assessment of dietary intake, especially energy and protein intake, is crucial for optimizing nutritional care and outcomes in patients with cancer. Validation of dietary assessment methods is necessary to ensure accuracy, but the validity of these methods in patients...

🗓️ 2024-07-08
📰 Publication: Current Opinion In Supportive And Palliative Care
Read MoreValidity of dietary intake methods in cancer cachexia.

Skeletal Muscle Proteome Modifications following Antibiotic-Induced Microbial Disturbances in Cancer Cachexia.

Cancer cachexia is an involuntary loss of body weight, mostly of skeletal muscle. Previous research favors the existence of a microbiota-muscle crosstalk, so the aim of the study was to evaluate the impact of microbiota alterations induced by antibiotics on...

🗓️ 2024-06-19
📰 Publication: Journal Of Proteome Research
Read MoreSkeletal Muscle Proteome Modifications following Antibiotic-Induced Microbial Disturbances in Cancer Cachexia.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!